Age-dependent effects of atorvastatin on biochemical bone turnover markers: A randomized controlled trial in postmenopausal women

Osteoporosis International

Volumn 15, Issue 6, 2004, Pages 459-467

  Berthold, Heiner K ^a,d   Unverdorben, Susanne ^a   Zittermann, Armin ^b   Degenhardt, Ralf ^a   Baumeister, Bernhard ^b   Unverdorben, Martin ^a   Krone, Wilhelm ^c   Vetter, Hans ^b   Gouni Berthold, Ioanna ^c  

^a Center for Cardiovascular Diseases   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Drug Commn of the Ger Med Assoc   (Germany)

Author keywords

Bone turnover; HMG CoA reductase inhibitors; Osteoporosis; Postmenopausal Randomized controlled trials; Statins

Indexed keywords

ALKALINE PHOSPHATASE; ATORVASTATIN; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OSTEOCALCIN; PARATHYROID HORMONE; PLACEBO;

ADULT; AGED; ARTICLE; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FRACTURE; HUMAN; IN VITRO STUDY; MULTICENTER STUDY; OSSIFICATION; OSTEOLYSIS; OUTPATIENT; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 3042634621     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00198-004-1598-1     Document Type: Article

References (46)

1. LaRosa JC, He J, Vupputuri S (1999) Effects of statins on risk of coronary heart disease: a meta-analysis of randomized controlled trials. JAMA 282:2340-2346
2. Schlienger RG, Meier CR (2003) HMG-CoA reductase inhibitors in osteoporosis-do they reduce the risk of fracture? Drugs Aging 20:321-336
3. Chan MHM, Mak TWL, Chiu RWK, Chow C-C, Chan IHS, Lam CWK (2001) Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab 86:4556-4559
4. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137-1142
5. Bauer DC, Sklarin PM, Stone KL, Black DM, Nevitt MC, Ensrud KE, Arnaud CD, Genant HK, Garnero P, Delmas PD, Lawaetz H, Cummings SR (1999) Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 14:1404-1410
6. Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone mineral density in postmenopausal women. Lancet 355:2218-2219
7. Watanabe S, Fukomoto S, Takeuchi Y, Nakano T, Fujita T (2000) Effects of one year treatment with statins on bone mass and metabolism (abstract). J Bone Miner Res 15[Suppl]:S194
8. Watanabe S, Fukomoto S, Takeuchi Y, Nakano T, Fujita T (2000) Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 110:584-587
9. Bauer DM, Mundy GR, Jamal SA, Black DM, Cauley JA, Duong T, Cummings SR (1999) Statin use, bone mass and fracture: an analysis of two prospective studies (abstract). J Bone Miner Res 14[Suppl]:S179
10. Chan KA, Andrade SE, Boles M, Buist DSM, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydroxymethylglutaryl- coenzyme A reductase and risk of fracture among older women. Lancet 355:2185-2188
11. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-3210
12. Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216
13. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Int Med 162:537-540
14. Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L (2002) Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 32:581-589
15. Bjarnason NH, Riis BJ, Christiansen C (2001) The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 12:380-384
16. Sirola J, Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, Saarikoski S (2002) Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 13:537-541
17. LaCroix AZ, Cauley JA, Jackson R, McGowen J, Pettinger M, Hsia J, Chen Z, Lewis CE, Bauer D, Daugherty S, McNeeley SG, Passero M (2000) Does statin use reduce risk of fracture in postmenopausal women? Results from women's health initiative study (WHI-OS) (abstract). J Bone Miner Res 15:S155
18. van Staa T-P, Wegman S, de Fries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850-1855
19. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N, The LIPID Study Group (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Lancet 357:509-512
20. Petersen TR, Kjekshus J (2000) Statin drugs and the risk of fracture. JAMA 284:1921-1922
21. Heart Protection Study Collaborative Group (2002) MRC/ BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
22. Ray WA, Daugherty JR, Griffin MR (2002) Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Injury Prevention 8:276-279
23. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley SG, Passaro MD, Jackson RD (2003) Statin use, clinical fracture, and bone density in postmenopausal women: Results from the Women's Health Initiative Observational Study. Ann Int Med 139:97-104
24. Cummings SR, Bauer DC (2000) Do statins prevent both cardiovascular disease and fracture? JAMA 283:3255-3257
25. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26-37
26. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Guttierez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949
27. van Beek E, Loewik C, van der Pluim G, Papapoulos S (1999) The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vivo: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14:722-729
28. Staal A, Frith JC, French MH, Swartz J, Gungor T, Harrity TW, Tamasi J, Rogers MJ, Feyen JH (2003) The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 18:88-96
29. Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 109:267-276
30. Bauer DC (2003) HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 14:273-282
31. Klausen T, Breum L, Sorensen HA, Schifter S, Sonne B (1993) Plasma levels of parathyroid hormone, vitamin D, calcitonin, and calcium in association with endurance exercise. Calcif Tissue Int 52:205-208
32. Fall PM, Kennedy D, Smith JA, Seibel MJ, Raisz LG (2000) Comparison of serum and urine assays for biochemical markers of bone resorption in potsmenopausal women with and without hormone replacement therapy and in men. Osteoporos Int 11:481-485
33. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, Seibel MJ (1999) Novel serum markers of bone resorption: clinical assessment and comparisons with established urinary indices. J Bone Miner Res 14:792-801
34. Szulc P, Chapuy P, Meunier J, Delmas PD (1993) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 91:1769-1774
35. Seibel MJ, Robins SP, Bilezikian JP (1997) Serum undercarboxylated osteocalcin and the risk of hip fracture. J Clin Endocrinol Metab 82:717-718
36. Pedrazzoni M, Alfano FS, Gatti C, Fantuzzi M, Girasole G, Campanini C, Basini G, Passeri M (1995) Acute effects of bisphosphonates on new and traditional markers of bone resorption. Calcif Tissue Int 57:25-29
37. Gamero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
38. Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, Karas RH (2003) Effects of statins on nonlipid serum markers associated with cardiovascular disease. Ann Int Med 139:670-682
39. Looker AC, Harris TB, Wahner HW (1992) Assessing hip fracture risk in a population-based health survey: the NHANES III osteoporosis component. Aging (Milano) 4:53-60
40. Melton LJ, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083-1091
41. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531-1538
42. van Daele PL, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JP, Birkenhager JC, Pols HA (1996) Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. Br Med J 312:482-483
43. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S (2001) Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscl Thromb Vasc Biol 21:1636-1641
44. Stein EA, Farnier M, Waldstreicher J, Mercuri M (2001) Effects of statins on biomarkers of bone metabolism: a randomised trial. Nutr Metab Cardiovasc Dis 11:84-87
45. Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I, WOSCOPS Group (2002) Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 90:731-736
46. Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 359:1841-1850